TP53 and neoplasm: Interestingly, our results in both, the experimental and validation cohorts suggest a tumor-suppressive role of RUNX1 in HGSOCs, but only in the subgroup without missense mutations in TP53, where its elevated expression correlated with the decreased risk of tumor recurrence.